美国疫苗伤害补偿计划(VICP)的实施表现:1988-2019年
本文回顾了美国疫苗伤害补偿计划(VICP)自1988年至2019年的实施经验,涵盖覆盖的疫苗与伤害类型、索赔情况及基金经济状况。综述显示疫苗具有优异的安全记录,提供了一些与疫苗接种操作本身相关的伤害证据,并讨论了基金的财务健康状况。
要点
- VICP通过疫苗消费税筹资,为声称因疫苗严重受伤者提供补偿申请与支付流程。
- 综述显示疫苗安全记录优异,并提供了一些与疫苗接种操作相关的伤害证据。
- 文章讨论了VICP基金的财务健康状况。
核心结论
- 综述显示疫苗具有优异的安全记录,提供了一些与疫苗接种操作本身相关的伤害证据,并讨论了基金的财务健康状况。
研究设计与样本
- 本文为综述,回顾美国疫苗伤害补偿计划(VICP)自1988年至2019年的实施经验,覆盖疫苗与伤害类型、索赔及基金经济状况。
主要发现
- 综述显示疫苗具有优异的安全记录。
- 提供了一些与疫苗接种操作本身相关的伤害证据。
- 讨论了VICP基金的财务健康状况。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The United States (US) highly values the individual and societal benefits of vaccination and invests significantly in vaccine development and use as part of its national vaccine enterprise. In 1986, recognizing the small, but non-zero risks associated with vaccines, the US created a mechanism to collect excise taxes on each dose of vaccine to fund a national Vaccine Injury Compensation Program (VICP). The VICP includes a system for those claiming serious injuries from vaccines to seek compensation, and a process to pay individuals with legitimate claims and their legal counsel. Given the maturity of the VICP, we review experience with the vaccines and injuries covered, claims, and economics of the fund. Our review shows the excellent safety track record of vaccines, provides some evidence of injuries related specifically to vaccine delivery, and discusses the financial health of the fund.
引用
- Thompson KM, Orenstein WA, Hinman AR, et al. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019. Vaccine. 2020. PMID: 31982259. doi:10.1016/j.vaccine.2020.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。